Original Article

You have full text access to this OnlineOpen article

The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma

  1. Yoichi Mizutani M.D.1,†,*,
  2. Hiromi Wada M.D.2,
  3. Osamu Yoshida M.D.3,
  4. Masakazu Fukushima Ph.D.4,
  5. Akihiro Kawauchi M.D.1,
  6. Masahiro Nakao M.D.1,
  7. Tsuneharu Miki M.D.1

Article first published online: 27 JUN 2003

DOI: 10.1002/cncr.11570

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 730–736, 15 August 2003

Additional Information

How to Cite

Mizutani, Y., Wada, H., Yoshida, O., Fukushima, M., Kawauchi, A., Nakao, M. and Miki, T. (2003), The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer, 98: 730–736. doi: 10.1002/cncr.11570

Author Information

  1. 1

    Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan

  2. 2

    Department of Thoracic Surgery, Graduate School of Medicine, Faculty of Medicine, Kyoto University, Kyoto, Japan

  3. 3

    Department of Urology, Graduate School of Medicine, Faculty of Medicine, Kyoto University, Kyoto, Japan

  4. 4

    Cancer Research Laboratory, Taiho Pharmaceutical Company Ltd., Saitama, Japan

  1. †

    Fax: (011) 81 75 251 5598

*Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 27 JUN 2003
  3. Manuscript Accepted: 12 MAY 2003
  4. Manuscript Revised: 1 MAY 2003
  5. Manuscript Received: 16 JAN 2003

Funded by

  • Japanese Urological Association
  • Japanese Ministry of Education, Culture, Sports, Science, and Technology. Grant Numbers: 14657410, 15390496

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (88K)

REFERENCES

  • 1
    Folkman J. What is the evidence that tumours are angiogenesis dependent? N Engl J Med. 1990; 285: 82–86.
  • 2
    O'Brien TS, Harris AL. Angiogenesis in urological malignancy. Br J Urol. 1995; 76: 675–682.
  • 3
    Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol. 1995; 2: 156–160.
    Direct Link:
  • 4
    Horak ER, Leek R, Klenk N, Le Jeune S, Smith K, Stuart N. Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet. 1992; 340: 1120–1124.
  • 5
    Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992; 267: 10931–10934.
  • 6
    Bicknell R, Harris AL. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer. 1991; 27: 781–785.
  • 7
    Nanus DM, Schmitz DB, Motzer RJ. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 1993; 85: 1597–1599.
  • 8
    Takahashi A, Sasaki H, Kim S. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placental growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994; 54: 4233–4237.
  • 9
    Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Dvorak H. Increased expression of vascular permeability factor (VEGF) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993; 143: 1255–1262.
  • 10
    Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989; 338: 557–562.
  • 11
    Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S. Angiogenic factor. Nature. 1992; 356: 668.
  • 12
    Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A. 1995; 92: 998–1002.
  • 13
    Haraguchi M, Kazutaka M, Uemura K, Sumizawa T, Furukawa T, Yamada K. Angiogenic activity of enzymes. Nature. 1994; 368: 198.
  • 14
    Zimmerman M, Seidenberg J. Deoxyribosyl transfer. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J Biol Chem. 1964; 239: 2618–2621.
  • 15
    Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F. Correlation of ovarian malignancy with expression of platelet-derived endothelial growth factor. J Natl Cancer Inst. 1994; 86: 1234–1238.
  • 16
    Umazono Y, Takebayashi Y, Nishiyama K, et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol. 1997; 15: 2570–2578.
  • 17
    SobinLH, WittekindC, editors. TNM classification of malignant tumors, 6th edition. New York: John Wiley & Sons, 2002.
  • 18
    Inaba M, Mitsuhashi J, Sawada H, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996; 87: 212–220.
  • 19
    Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986; 46: 20–28.
  • 20
    Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4: 1013–1019.
  • 21
    Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull. 1996; 19: 1407–1411.
  • 22
    Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by Adriamycin. Cancer Res. 2000; 60: 2912–2918.
  • 23
    Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 2001; 92: 287–293.
    Direct Link:
  • 24
    Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res. 1995; 55: 590–596.
  • 25
    Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer. 2002; 38: 167–176.
  • 26
    Kinsui H, Ueda T, Suzuki H, et al. Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method. Jpn J Cancer Res. 2002; 93: 340–345.
  • 27
    Pinedo HM, Peters GJ. 5-fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988; 6: 1653–1664.
  • 28
    Santi DV, McHenry CS, Sommer H. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridine. Biochemistry. 1974; 13: 471–480.
  • 29
    Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999; 5: 2289–2296.
  • 30
    Matsushita S, Nitanda T, Furukawa T, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999; 59: 1911–1916.
View Full Article (HTML) Get PDF (88K)